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Reversibility of urinary tract abnormalities due to Schistosoma
haematobium infection. In view of the controversial results regarding
reversibility of urinary tract lesions due to Schistosoma haematobium
infection, 103 patients in the People's Republic of Congo were followed
up one year after treatment with Praziquantel (40 mg/kg body wt) by
means of ultrasonography. The study group consisted mainly of chil-
dren. Before therapy a total of 113 lesions were detected in the lower
urinary tract. These consisted of bladder wall enlargements (N = 53),
enlargements of the bladder wall in combination with singular (N = 16)
or multiple polyps (N 30), vesical calcifications (N = 10), and cases
with cystitis cystica (N = 4). One year after therapy, a drastic reduction
of ova output was observed, and only eight pathological abnormalities
of the lower urinary tract were still detectable. Vesical calcifications
persisted in four out often cases. Urinary tract obstructions of different
degrees (N = 42) showed a comparably marked reversibility. It was
concluded that, in children, the resolution of bladder lesions induced by
urinary schistosomiasis resulted in reversibility of urinary tract obstruc-
tions one year after treatment with Praziquantel.
Previous investigations about urinary schistosomiasis have
clearly shown that egg output and pathological urine findings
such as proteinuria, hematuria, and leukocyturia are reversible
after antisehistosomal treatment 1—31. Controversial results,
however, have been published regarding the prognosis of
urinary tract lesions following treatment. Davis found no reduc-
tion of obstructive uropathy after therapy 4], whereas other
studies indicated reversibility of pathological findings in the
upper and lower urinary tract [5—7].
The present investigation provides parasitological and
ultrasonographical follow—up data of urinary tract abnormalities
in patients with Schistosorna haematobiu,n infection one year
after therapy with Praziquantel.
Methods
Study area and patients
The investigations were conducted in Bouansa in the Peo-
ple's Republic of Congo, an area with S. haernatobium infection
only, but not S. mansoni or S. intercalatum. A community
study was performed between May and July 1984 assessing
pathological ultrasonographical findings of the urinary tract
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induced by Schistosoma huematohium infection. Details of this
investigation are published elsewhere [8]. The study was con-
ducted parallel to the bilateral German—Congolese antischisto-
somiasis control program "Lutte contre Ia Schistosomiase". A
prevalence of urinary schistosomiasis of 10% was found in the
study area, Bouansa, when 10 ml urine samples of more than
90% of the cities' total population of 7000 inhabitants were
examined. In the course of the concomitant vertical mass
treatment program, all infected individuals discovered in
Bouansa and surrounding villages were treated with
Praziquantel (40 mg/kg body wt).
A subset of 213, mostly heavily infected patients was exten-
sively examined, including abdominal ultrasonography [8]. Of
those, 126 predominantly young patients were found to have
pathological ultrasonographical findings of the urinary tract
before therapy, which were attributable to S. haematobiurn
infection. All 213 patients initially admitted to the study were
treated with Praziquantel (40 mg/kg body wt) under surveillance
of the main investigator in June 1984,
103 patients could be followed—up I 1 months after therapy
and underwent a second ultrasonographical examination. The
age range was from six to 65 years, but only 11 patients were
older than 18 years. Informed consent was obtained in French
from the parents or family representatives after explanation of
the diagnostic procedure.
Urine examination
Urine samples were collected on two consecutive days be-
tween 11 a.m. and 2 p.m., because of the day—to—day and
circadian variation of ova output and pathological urine findings
[9, 10]. Number and viability of eggs was assessed by a
sensitive filtration technique [11]. Proteinuria was quantita-
tively determined after centrifugation of urine by the Coomassie
blue dye binding test [12]. Erythrocyturia and leukocyturia
were quantified in a Neubauer chamber.
Ultrasound examination
During follow—up studies in May 1985, a portable digital
gray—scale ultrasound unit with a 3.5 MHz linear array real time
scanner was used (Fa. Hellige, Freiburg, FRG). The bladder
was evaluated only when filled with urine, and the bladder wall
thickness (BWT) was measured in the dorsal part of the
bladder. Pathological findings in the lower urinary tract were
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Table 1. Egg output, proteinuria, erythrocyturia and leukocyturia of
103 patients with urinary schistosomiasis before and one year after
treatment with Praziquantel (medians and 95% confidence limits)
Before therapy After therapy
(June 1984) (May 1985)
N=103 N=103
Number of patients excreting
viable ova 103 26
Median ova output (eggs/b ml) 246 0
(154—300) (0—0)
Median proteinuria (mg/liter) 630 68
(410—840) (56—80)
Median erythrocyturia (cells/1d) 972 0
(720—1188) (0—1)
Median leukocyturia (cells/1.d) 468 0
(412—648) (0—3)
classified as reported in previous publications by our working
group on ultrasonography in urinary schistosomiasis [8, 13—15].
Isolated bladder wall enlargement (BWE) was defined as a
continuously enlarged bladder wall in excess of 5 mm with a
smooth or partly wave—like inner contour. When circumscript
mucosa dilatations protruded more than 5 mm from the inner
bladder wall into the bladder lumen, this was classified as BWE
in combination with singular or multiple polyps, since such
polyps were always associated with BWE. Vesicle calcifica-
tions were sonographically characterized as minute spots of
high echogenicity, usually without distal shadowing [13, 14].
Cystitis cystica was diagnosed when several small echo—free
holes without pulsations were detected in an enlarged bladder
wall, mimicking an almost sieve—like appearance [13].
In the upper urinary tract, a continuous dilatation of the renal
collecting system in excess of 5 mm plus dilatation of the
pelvicalyceal structures was regarded suggestive of urinary
tract obstruction grade 1. The confirmative criterium for the
diagnosis of urinary tract obstruction (UTO) was considered a
persistence of this dilatation of the renal pelvis 30 minutes after
voiding of the bladder, since ureterovesical reflux was then
thought to be most unlikely. UTO II was diagnosed when the
dilatation of the renal collecting system was more than 1 cm in
combination with a marked prominence of the pelvicalyceal
structures. UTO Grade III occurred when, in addition to UTO
II, the ipsilateral ureter could be visualized on its total exten-
sion into the lower pelvis and demonstrated in the dorsal
perivesical area.
Statistical evaluation
Results of ova output, pathological urine findings, bladder
wall enlargements and dilatations of the renal collecting system
were calculated as medians and 95% confidence limits. Signif-
icance of difference was tested with the Wilcoxon matched
pairs signed rank test.
Results
Treatment with Praziquantel (40 mg/kg body wt) resulted in a
marked reduction of egg excretion and pathological urine
findings one year after therapy (Table 1). In the study group the
median ova output in 1984 was 246 per 10 ml urine and nil in
1985. Twenty—six patients still passed viable ova (range 0.1 to
160 per 10 ml urine), but only one of them had an output of more
Table 2. Frequency of pathological ultrasonographical findings of the
lower urinary tract in 103 patients with urinary schistosomiasis before
and one year after application of Praziquantel
Number of patients with urinary
tract lesions
Before therapy After therapy
1984 1985
Isolated bladder wall enlargement
(BWE) 53 3
BWE plus singular polyp 16 1
BWE plus multiple polyps 30 0
Vesical calcifications 10 4
Cystitis cystica 4 0
Table 3. Bladder wall thickness in mm before and one year after
treatment with Praziquantel in groups of patients showing different
vesical lesions before therapy
Bladder wall thickness in mm
Before therapy
1984
After therapy
1985
Patients with isolated BWE
(N = 53)
Patients with BWE plus
singular polyp (N = 16)
Patients with BWE plus
multiple polyps (N = 30)
7
7—8
8
8—9
10
9—10
3
3—4
4
2—4
3
3—4
than 100 eggs per 10 ml. Accordingly, physiological proteinuria,
erythrocyturia, and leukocyturia were found one year after
therapy. This reduction of urine findings was paralleled by a
marked reversibility of pathological ultrasonographical abnor-
malities in the lower urinary tract (Table 2), In 1984, 103
patients revealed a total number of 113 pathological vesical
lesions, whereas only eight sonographical abnormalities of the
lower urinary tract were detected in 1985. These consisted
mainly of isolated bladder wall enlargements and vesical calci-
fications. The only singular polyp, during follow—up investiga-
tions, was encountered in a patient who showed active S.
haematobium infection, that is, 71 viable ova per 10 ml urine.
In order to provide quantitative data concerning the reduc-
tion of bladder wall enlargement (BWE) after therapy, the
medians and 95% confidence limits (95% CL) of bladder wall
thickness (BWT) before and after therapy were calculated
(Table 3). Patients with isolated BWE showed a median BWT of
7 mm (95% CL 7-8) in 1984, as opposed to 3 mm (95% CL 3-4)
one year after therapy. The corresponding values for the groups
with BWE plus singular or multiple polyps were 8 mm (95% CL
8-9) and 10 mm (95% CL 9-10) before therapy, as compared to
4 mm (95% CL 2-4) and 3 mm (95% CL 3-4) one year later. The
differences of BWT before and after administration of
Praziquantel were significant (P < 0.001) for all three groups of
patients.
Urinary tract obstruction (UTO) reversed in the great major-
ity of patients one year after treatment (Table 4). Before
therapy, 37 patients had a total of 42 kidneys with
ultrasonographically—defined obstructive uropathy, including
five cases with bilateral UTO. One year later UTO persisted in
four patients. A ten—year—old boy with UTO grade III in 1984
584 Doehring ci of
Table 4. Frequency of urinary tract obstruction in 103 patients with
urinary schistosomiasis before and after therapy with Praziquantel
Number of kidneys with or without UTO
Before therapy
1984
After therapy
1985
UTO absent
UTO grade 1
UTO grade 11
UTO grade III
164
25
12
5
201
4
1
0
still revealed UTO grade II at the time of follow—up. In all other
cases the dilatation of the renal collecting system was mild (that
is, less than 8 mm). One patient without UTO in 1984 revealed
a dilatation of the renal sinus of 7 mm one year after treatment.
This patient showed no BWE and no excretion of S.
hoematobium ova.
The median dilatation of the renal collecting system before
therapy was 8 mm (95% CL 7-9) in patients with UTO grade I,
14 mm (95% CL 12-17) as well as 20 mm (95% CL 14-25) in
those with UTO grade II and grade III. A significant reduction
of the values to 1 mm (95% CL 0-3), 2 mm (95% CL 0-3) and 2
mm (95% CL 0-12), was seen a year later (P < 0.00 1).
Discussion
The results of this study indicate reversibility of urinary tract
abnormalities in young patients with S. haernatobium infection
one year after treatment with Praziquantel. This is in accord-
ance with a radiological study by Farid et al [16] and other
investigators who have administered antischistosomal drugs
other than Praziquantel [5—7, 17—20]. By contrast, different
studies reported no or substantially less reversibility of urinary
tract lesions following treatment [4, 21, 221. In comparing the
different results of these investigations, the number of patients
examined, the effectiveness of therapy, the interval of follow—
up, the prevalence of disease in the study area including the
chance of reinfection, and the age of the patients investigated,
have to be taken into consideration. Some authors have only
reported on relatively small numbers of patients, that is, less
than 10 patients [5, 16, 17].
The studies of MacDonald and Forsyth as well as
MacDonald, Forsyth, and Rashid [21, 22], indicating persis-
tence of urinary tract abnormalities after treatment with
antimonials, were performed on a comparable number of pa-
tients as in the present investigation. Their differing results may
partly be explained by the fact that more advanced antischisto-
somal compounds such as Praziquantel have a higher efficiency
than antimonials. Reinfection may have interfered with the
resolution of pathological lesions in the investigation of Mac-
Donald and Forsyth [21], as suggested by a 40% prevalence of
urinary schistosomiasis at their time of follow—up. Reinfection
of urinary schistosomiasis in our study area was very low due to
a primarily low prevalence of disease and vertical control
measures in the form of mass treatment performed in 1984.
Thus, the great majority of infected patients in the investigated
city were effectively treated. The transmission rate of urinary
schistosomiasi s, therefore, substantially declined and immedi-
ate reimportation of disease transmission from neighbouring
villages was unlikely, since mass treatment also enclosed stir-
rounding human habitats. In contrast, reinfection under
hyperendemic conditions without mass treatment can be ex-
pected to begin four months after antischistosomal therapy [31.
Davis [4] found no reversibility of urinary tract abnormalities
in 20 to 40-year—old patients after therapy with antimonials. It
has been repeatedly pointed out that fibrotic changes of the
lower urinary tract caused by long—standing disease in adults
would not resolve, whereas obstruction of urine flow caused by
vesical polyps and edema would be reversible [6, 7, 19]. In our
opinion, therefore, the age of patients under investigation is
very important.
Three other studies have indicated regression of bladder
polyps in individual patients after administration of antimonials
[5, 23, 24]. The most striking effect of Praziquantel on the lower
urinary tract was the almost radical and longstanding reversi-
bility of bladder polyps. The only vesical polyp encountered
during follow—up was seen in a patient with apparent schisto-
somal reinfection. The present study together with a pilot
investigation on six patients of the same study area [15] seem to
he the first to sonographically evaluate the effect of Prazi-
quantel on urinary tract lesions in patients with urinary schis-
tosomiasis.
The remarkably low amount of persons with bladder wall
enlargements after therapy, which was detected in only four out
of 103 patients during follow—up, was considered insignificant
and unrelated to urinary schistosomiasis except in one case.
This percentage may indicate the spontaneous occurrence of
bladder wall enlargements in the study area. Examination of an
age matched group of healthy Congolese controls without
urinary schistosomiasis and patients with only minimal Schis-
tosoma haernatobium infection (that is, excretion of less than
20 eggs per 10 ml urine) showed a comparable rate of bladder
wall enlargements of 4% [8].
Calcifications of the bladder showed the highest rate of
persistence. This finding is in accordance with other studies [4,
6, 21], and can be explained by the fact that vesical calcifica-
tions represent calcified ova which remain trapped in the
bladder tissue [251.
Urinary tract obstruction represents the most important
functional impairment of S. haematobium infection involving
the potential risk of renal dysfunction [261 and a considerable
mortality rate [27, 28]. In all patients of this study moderate and
severe urinary tract obstruction markedly regressed after ther-
apy. Only one patient was left with a definite residual lesion of
the upper urinary tract. Three children still revealed mild
dilatations of the renal collecting system one year after therapy.
This significant reversibility of obstructive uropathy was
thought to he due to the resolution of inflammatory and
polypoid changes in the lower urinary tract.
MacDonald and Forsyth [211 assessed the effect of
antischistosomal therapy on urinary tract lesions by radiologi-
cal techniques and pointed out the high organizational effort of
such an approach. In the present investigation, the use of a
portable ultrasound unit proved to be a practical diagnostic tool
to evaluate pathological abnormalities induced by urinary schis-
tosomiasis. This was also described by Degremont et al [29].
Furthermore, in the present study ultrasonography, which is
much easier to perform especially under field conditions, was
shown to be a rapid method for follow—up examinations of
patients. The results of our data support modern concepts of
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combatting against urinary schistosomiasis, which try to reduce
morbidity with effective mass chemotherapy [301. The impor-
tance of early antischistosomal treatment in childhood, when
pathological conditions are still reversible, is emphasized.
Ultrasonography may serve as an important diagnostic method
of nephrological surveys in the tropics.
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